GNMX - Aevi Genomic Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Annual

Cash Flow

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Cash flows from operating activities
Net Income
-22,359
-30,775
-34,714
-41,904
-37,992
Depreciation & amortization
52
65
112
268
240
Deferred income taxes
-
-
-
-
-
Stock based compensation
2,439
3,090
3,368
6,788
12,388
Change in working capital
-971
971
-2,044
2,099
-102
Accounts receivable
-
-
-
-
-432
Inventory
-
-
-
-
-
Accounts Payable
-1,161
639
806
-1,185
246
Other working capital
-20,839
-26,649
-33,250
-32,970
-24,534
Other non-cash items
-
-
-
6,788
-269
Net cash provided by operating activites
-20,839
-26,649
-33,246
-32,749
-24,347
Cash flows from investing activities
Investments in property, plant and equipment
-
-
-4
-221
-187
Acquisitions, net
-
-
-
-
-
Purchases of investments
-
-
-
-
-
Sales/Maturities of investments
-
-
-
-
-
Other investing activites
-
-
-
0
0
Net cash used for investing activites
0
0
148
-221
-187
Cash flows from financing activities
Debt repayment
-
-
-
-
-
Common stock issued
-
4,962
26,970
19,563
42,882
Common stock repurchased
-
-
-
-
-
Dividends Paid
-
-
-
-
-
Other financing activites
-
-
-
0
0
Net cash used privided by (used for) financing activities
5,125
4,996
26,989
19,744
44,310
Net change in cash
-15,714
-21,653
-6,109
-13,226
19,776
Cash at beginning of period
19,151
33,729
39,838
53,064
33,288
Cash at end of period
3,437
12,076
33,729
39,838
53,064
Free Cash Flow
Operating Cash Flow
-20,839
-26,649
-33,246
-32,749
-24,347
Capital Expenditure
-
-
-4
-221
-187
Free Cash Flow
-20,839
-26,649
-33,250
-32,970
-24,534